Literature DB >> 16257876

Isolated office hypertension: a 3-year follow-up study.

Anna M Grandi1, Francesco Solbiati, Emanuela Laurita, Elena Cassinerio, Chiara Marchesi, Francesca Piperno, Andrea Maresca, Luigina Guasti, Achille Venco.   

Abstract

The study aimed to evaluate, over a 3-year period, the progression towards sustained hypertension and left ventricular (LV) changes in patients with isolated office (IO) hypertension (office BP>140 and/or 90 mmHg, daytime BP<130/80 mmHg). After 3 years from the basal evaluation, 38 subjects with basal normal BP and 42 subjects with basal IO hypertension underwent a second 24-h BP monitoring and echocardiography; 19 patients of the basal IO hypertension group were not revaluated because they had already developed ambulatory hypertension and were on antihypertensive treatment. At the second evaluation, the 38 normotensive subjects had unchanged BP and LV parameters; 25 IO hypertensives have developed sustained hypertension. Considering them together with the 19 patients already treated, 72% of 61 IO hypertensives developed ambulatory hypertension over a 3-year period. The patients who subsequently developed hypertension differed from the group who did not only for lower basal values of LV diastolic parameters; all the patients with basal LV hypertrophy and/or preclinical diastolic impairment subsequently developed sustained hypertension. In conclusion, IO hypertensive patients show a high rate of progression towards sustained hypertension. Basal LV hypertrophy and/or preclinical diastolic dysfunction were the only markers of a greater risk of becoming hypertensives.

Entities:  

Mesh:

Year:  2005        PMID: 16257876     DOI: 10.1080/08037050500331496

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  1 in total

Review 1.  The Role of Out-of-Clinic Blood Pressure Measurements in Preventing Hypertension.

Authors:  Yi Chen; Dong-Yan Zhang; Yan Li; Ji-Guang Wang
Journal:  Curr Hypertens Rep       Date:  2018-07-30       Impact factor: 5.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.